Introduction

The effect of 1-piperidinepropionic acid on Serpin 3 molecules has proven effective in the reduction of the fibrotic damage to tissues affected by fibrotic diseases.  Such a compound will be a useful for the development of effective drug treatments for diseases that are currently without  a cure.

Technical features

This patent regards the use of 1-piperidinepropionic acid for the treatment of fibrotic diseases such as: chronic hepatitis, steatohepatitis, sclerosing cholangitis, cirrhosis of the liver, cystic fibrosis, idiopathic pulmonary fibrosis, kidney fibrosis and connectivitis. For the treatment of such diseases the molecule SeprinB3 has been identified as an effective target, since it is a protease inhibitor. Laboratory samples of diseased fibrotic tissue treated with 1-piperidinepropionic acid showed a visible reduction of tissue damage and degree of fibrosis. This compound is readily available, stable,  well tolerated in experimental models and is inexpensive. Its application will be of interest for the pharmaceutical industry that is dedicated to hepatic, rheumatic and pneumological diseases. Currently the technology in a pre-clinical development phase.

Possible Applications

• Treatment of chronic fibrosing diseases;
• Treatment of chronic hepatitis, steatohepatitis, sclerosing cholangitis, liver cirrhosis, cystic fibrosis, idiopathic pulmonary fibrosis, connective tissue diseases, renal fibrosis.

Advantages

• Effective treatments currently unavailable;
• Readily available compound;
• Stable compound.